V. Bryan Lawlis
V. Bryan Lawlis's purchase track record
V. Bryan Lawlis has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/9/2025 | GERN | $16K | +8.5% | -9.3% | +18.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
Transaction History
| GERN | ▲ Buy | Open Market | 13,300 | $16K | 5/9/2025 | View on chart |
| GERN | ▲ Buy | Option Exercise | 35,000 | $68K | 5/15/2024 | View on chart |
| GERN | ▼ Sell | Open Market | 35,000 | $131K | 5/15/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 4,190 | $0 | 5/23/2023 | View on chart |
| GERN | ▲ Buy | Option Exercise | 35,000 | $39K | 5/11/2023 | View on chart |
| GERN | ▼ Sell | Open Market | 35,000 | $105K | 5/11/2023 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 8,500 | $576K | 4/3/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 8,500 | $825K | 4/3/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 4,980 | $0 | 5/24/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 4,250 | $159K | 4/14/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 4,250 | $356K | 4/14/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 4,250 | $159K | 1/14/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 4,250 | $372K | 1/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
GERN Highlights Imetelstat at International Hematology Congresses
Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.
GERN Highlights Imetelstat at International Hematology Congresses. Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.